Argatroban use in heparin-induced thrombocytopenia.
Research article published in Expert opinion on pharmacotherapy (2008)
Abstract
BACKGROUND: Heparin-induced thrombocytopenia (HIT) is a serious, life-threatening complication which occurs in 1-3% of patients receiving heparin. Patients with untreated HIT have an up to 50% risk of developing life- and limb-threatening thromboembolic complications. Treatment is based upon clinical suspicion, stopping heparin therapy and initiation of anticoagulation with a rapidly acting alternative non-heparin anticoagulant, such as argatroban-a hepatically excreted direct thrombin inhibitor which is effective in the treatment of HIT. OBJECTIVE: To summarize the pharmacological and clinical data, and discuss the impact of argatroban in the current treatment of HIT. METHODS: A literature search was performed with the aid of Pubmed and Google. Search parameters of 'argatroban', 'heparin-induced thrombocytopenia' and 'treatment' were input into both search engines. CONCLUSION: Argatroban is a safe and effective treatment for HIT. In patients taking other hepatically cleared medications, lower initial doses may have to be used to avoid over-anticoagulation.
Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.
Resumen
Argatroban use in heparin-induced thrombocytopenia.
Por qué esto importa para la hirudoterapia
Esta revisión resume los datos farmacológicos y clínicos del argatroban, un inhibidor directo sintético de la trombina, en el tratamiento de la trombocitopenia inducida por heparina (HIT). Los inhibidores directos de la trombina representan una clase de fármacos conceptualmente inspirada en anticoagulantes naturales de la sanguijuela como la hirudina. Sin embargo, el argatroban es una molécula completamente sintética y este artículo no menciona en absoluto las sanguijuelas, la hirudoterapia ni el secretoma de la sanguijuela. Por lo tanto, su relevancia para la American Society of Hirudotherapy es esencialmente inexistente, sirviendo solo como una nota tangencial sobre un tipo diferente de anticoagulante.
Citación
Argatroban use in heparin-induced thrombocytopenia.
Boggio et al. · Expert opinion on pharmacotherapy, 2008
Contexto clínico relacionado
Explore cómo esta investigación se conecta con la práctica clínica
Añadido a la biblioteca ASH: May 28, 2026 · Última actualización del sitio: June 18, 2026